AVITA Medical Schedules Third Quarter 2026 Financial Results Announcement
AVITA Medical has scheduled the release of its financial results for the third quarter of 2026.
Economy · News reference
AVITA Medical Announces PermeaDerm-I Study Met Primary Endpoint, Delivering Clinically Comparable Outcomes To Cadaveric Allograft With 70% Cost Reduction
Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001) 96% reduction in preparation time and comparable clinical
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Maintains Buy on AVITA Medical, Raises Price Target to $15
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $11 to $15.
AVITA Medical Q2 2026 Earnings Call Transcript
On Thursday, AVITA Medical (NASDAQ:RCEL) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts
TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $14
TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $14.